SCHEMBL4937243

SCHEMBL4937243

CC(C)(C)CC(=O)CP(=O)(O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENO1 P06733 1/20 0.42
LMNA P02545 2/20 0.42
MEN1 O00255 1/20 0.42
HPGD P15428 1/20 0.42
TSHR P16473 1/20 0.42
BLM P54132 1/20 0.42
KMT2A Q03164 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
PGK1 P00558 1/20 0.36
PGK2 P07205 1/20 0.36
GRM4 Q14833 1/20 0.34
GRIN2D O15399 1/20 0.31
GRIN3B O60391 1/20 0.31
GRIN1 Q05586 1/20 0.31
GRIN2A Q12879 1/20 0.31
GRIN2B Q13224 1/20 0.31
GRIN2C Q14957 1/20 0.31
GRIN3A Q8TCU5 1/20 0.31
FDPS P14324 1/20 0.31
KDM4E B2RXH2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9003783 0.76 BLM (0.39) ENO1LMNAMEN1HPGDTSHR
SCHEMBL1549162 0.76 PPARD (0.50) TSHRTDP1
SCHEMBL9003789 0.76 BLM (0.39) ENO1LMNAMEN1HPGDTSHR
SCHEMBL1549161 0.75
SCHEMBL28228676 0.74 MEN1 (0.59) ENO1LMNAMEN1HPGDTSHR
SCHEMBL818454 0.74 HMGCR (0.40) MEN1HPGDTSHRKMT2ATDP1
SCHEMBL26699687 0.72 TSHR (0.43) TSHRTDP1MAPK1
SCHEMBL9221547 0.71 MEN1 (0.39) LMNAMEN1HPGDTSHRBLM
SCHEMBL3074006 0.70
SCHEMBL14282026 0.69 HMGCR (0.36) MEN1HPGDTSHRKMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023226950-A1 PEPTIDOMIMETIC STAT PROTEIN DEGRADER, COMPOSITION AND USE THEREOF 杭州和正医药有限公司 2023-11-30 WO disclosed
US-7419999-B2 Gamma lactams as prostaglandin agonists and use thereof APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2008-09-02 US disclosed
EP-1556347-A4 GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF APPLIED RESEARCH SYSTEMS (AN) 2006-08-09 EP disclosed
US-20050288357-A1 Gamma lactams as prostaglandin agonists and use thereof APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2005-12-29 US disclosed
EP-1556347-A2 GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF Applied Research Systems ARS Holding N.V. (AN) 2005-07-27 EP disclosed
WO-2003103604-A2 GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF APPLIED RESEARCH SYSTEMS ARS HOLDING N.V (AN) 2003-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288357-A1 Gamma lactams as prostaglandin agonists and use thereof PGF, HPGDS, PTGIS ENO1 1761/4885LMNA 1060/4885MEN1 3591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.